Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HUIT, C. S.
Right arrow Articles by FAHN, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by HUIT, C. S.
Right arrow Articles by FAHN, S.
NEUROLOGY 1977;27:505
© 1977 American Academy of Neurology

Interaction between bromocriptine and levodopa

Biochemical basis for an improved treatment for parkinsonism

CHERYL S. HUIT, B.A., STUART R. SNIDER, M.D. and STANLEY FAHN, M.D.

Department of Neurology, Columbia University College of Physicians and Surgeons, New York.

The present investigation examined the biochemical interaction of bromocriptine and levodopa with respect to monoamine and gamma-aminobutyric acid metabolism in the brain. Rats were treated with levodopa, 250 mg per kilogram of body weight intraperitoneally, with or without carbidopa, 25 mg per kilogram, 1 or 2 hours before sacrifice. Some were also given bromocriptine, 5.0 mg per kilogram, 4 hours before sacrifice. Rats were killed 1 and 2 hours after levodopa and brain levels of gamma-aminobutyric acid and monoamines, and their metabolites were measured. Dopamine levels and metabolism were not markedly altered when bromocriptine was added to levodopa treatment. The level of serotonin, which was reduced 25 to 40 percent by levodopa alone, was close to normal with the combination treatment. Serotonin metabolism was also enhanced by the addition of bromocriptine as shown by increased levels of 5-hydroxyindoleacetic acid. The results suggest that bromocriptine not only may improve the motor disorder of parkinsonism but also may reduce some side effects of levodopa therapy, such as depression, which could be due to serotonin depletion.

Reprint requests should be addressed to Dr. Fahn, Department of Neurology, 630 West 168th Street, New York, NY 10032.

Ms. Hutt was the recipient of the Saul R. Korey Award for this work, which was supported by the Parkinson's Disease Foundation and the Samuel A. and Katharine B. Berger Foundation.

Received for publication August 2, 1976.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1977 by AAN Enterprises, Inc.